JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lasdun, A.
Right arrow Articles by Orlowski, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lasdun, A.
Right arrow Articles by Orlowski, M.

Inhibition of endopeptidase 24.15 slows the in vivo degradation of luteinizing hormone-releasing hormone

A Lasdun, S Reznik, CJ Molineaux and M Orlowski

Department of Pharmacology, Mount Sinai School of Medicine, City University of New York.

Endopeptidase (EP) 24.15 cleaves the Tyr5-Gly6 bond of luteinizing hormone-releasing hormone (LHRH) (pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro- Gly-NH2), and is the primary LHRH degrading enzyme in pituitary and hypothalamic membrane preparations. Potent and specific inhibitors were used to identify the enzymes involved in the in vivo degradation of LHRH. After i.c.v. administration of LHRH, only about 1% of the peptide was recovered from brain after 1 hr. Concurrent administration of LHRH and N-[1-(RS)-carboxy-3-phenylpropyl]-Ala-Ala-Phe-p-aminobenzoate (cFP- AAF-pAB), a specific inhibitor of EP 24.15, led to a more than 10-fold increase in LHRH recovery. Administration of N-[1-(RS)-carboxy-3- phenylpropyl]-Phe-pAB (cFP-F-pAB) or captopril, inhibitors of "enkephalinase" (EP 24.11) and angiotensin converting enzyme, respectively, did not significantly increase LHRH recovery. Intravenous administration of LHRH and either cFP-F-pAB or cFP-AAF-pAB but not captopril, led to an increase in the half-life of LHRH from 10 min to 15 and 20 min, respectively. Concurrent administration of both inhibitors resulted in a dramatic 8-fold increase in the half-life of LHRH, similar to values reported for "superactive" analogs of LHRH which are rendered resistant to enzymatic degradation by introduction of a D-amino acid in position 6. Concentrations of plasma LHRH 65 to 80 min after administration of inhibitors were 100- to 200-fold higher than those in controls. The potentiating effect of cFP-F-pAB resulted from inhibition of the in vivo degradation of cFP-AAF-pAB by EP 24.11.(ABSTRACT TRUNCATED AT 250 WORDS)

Volume 251, Issue 2, pp. 439-447, 11/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
Exp. Biol. Med.Home page
K. Walters, I. N. Wegorzewska, Y.-P. Chin, M. G. Parikh, and T. J. Wu
Luteinizing Hormone-Releasing Hormone I (LHRH-I) and Its Metabolite in Peripheral Tissues
Experimental Biology and Medicine, February 1, 2008; 233(2): 123 - 130.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
C. N. Shrimpton, A. I. Smith, and R. A. Lew
Soluble Metalloendopeptidases and Neuroendocrine Signaling
Endocr. Rev., October 1, 2002; 23(5): 647 - 664.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
C. Yamanaka, M. C. Lebrethon, E. Vandersmissen, A. Gerard, G. Purnelle, M. LeMaitre, S. Wilk, and J. P. Bourguignon
Early Prepubertal Ontogeny of Pulsatile Gonadotropin-Releasing Hormone (GnRH) Secretion: I. Inhibitory Autofeedback Control through Prolyl Endopeptidase Degradation of GnRH
Endocrinology, October 1, 1999; 140(10): 4609 - 4615.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
P. M. Cummins, A. Pabon, E. H. Margulies, and M. J. Glucksman
Zinc Coordination and Substrate Catalysis within the Neuropeptide Processing Enzyme Endopeptidase EC 3.4.24.15. IDENTIFICATION OF ACTIVE SITE HISTIDINE AND GLUTAMATE RESIDUES
J. Biol. Chem., June 4, 1999; 274(23): 16003 - 16009.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. C. S. Saphire, S. J. Bark, and L. Gerace
All Four Homochiral Enantiomers of a Nuclear Localization Sequence Derived from c-Myc Serve as Functional Import Signals
J. Biol. Chem., November 6, 1998; 273(45): 29764 - 29769.
[Abstract] [Full Text] [PDF]


Home page
Endocr. Rev.Home page
A. E. Herbison
Multimodal Influence of Estrogen upon Gonadotropin-Releasing Hormone Neurons
Endocr. Rev., June 1, 1998; 19(3): 302 - 330.
[Abstract] [Full Text]


Home page
J. Biol. Chem.Home page
J. Jirácek, A. Yiotakis, B. Vincent, A. Lecoq, A. Nicolaou, F.édér. Checler, and V. Dive
Development of Highly Potent and Selective Phosphinic Peptide Inhibitors of Zinc Endopeptidase 24-15 Using Combinatorial Chemistry
J. Biol. Chem., September 15, 1995; 270(37): 21701 - 21706.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
J. W. Tullai, P. M. Cummins, A. Pabon, J. L. Roberts, M. C. Lopingco, C. N. Shrimpton, A. I. Smith, J. A. Martignetti, E. S. Ferro, and M. J. Glucksman
The Neuropeptide Processing Enzyme EC 3.4.24.15 Is Modulated by Protein Kinase A Phosphorylation
J. Biol. Chem., November 17, 2000; 275(47): 36514 - 36522.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 1989 by the American Society for Pharmacology and Experimental Therapeutics.